- Academic Affairs
- Accountability and Compliance
- Administration and Finance
- Center for Health and Homeland Security
- Center for Information Technology Services
- Communications and Public Affairs
- Community Engagement
- Government Affairs
- Human Resource Services
- Office of Philanthropy
- Operations and Planning
- Police and Public Safety
- President's Office
- Research and Development
- University Counsel
University of Maryland, Baltimore (UMB) investigators who use drugs or substances controlled by the Drug Enforcement Administration (controlled substances) for research must comply with applicable federal and state laws. UMB must oversee research use of controlled substances at UMB and in off-campus facilities controlled by UMB. UM Policy VI - 99.00(A), POLICY ON RESEARCH USE OF CONTROLLED SUBSTANCES establishes responsibilities and procedures for research use of Controlled Substances.
This policy applies to acquisition, use, manufacture, storage, and disposal and lawful disposition of controlled substances used for research purposes. This policy applies to all registrants and those authorized persons working with controlled substances under registrant supervision.
This policy does not apply to licensed practitioners with respect to (a) dispensing controlled substances in the course of their professional practices, as authorized by their licenses as health care practitioners, or (b) dispensing controlled substances in the course of human subjects research within any hospital in the University of Maryland Medical Center, at the Baltimore Veterans Affairs Medical Center, or at any other health care facility that takes responsibility for the inventory and control of the controlled substances being used in research.
To begin the data collection process, Environmental Health and Safety (EHS) is asking all UMB investigators with a state and federal registration to submit information on the Controlled Substance Information Form. EHS will be in contact with each registrant to collect additional information and discuss compliance with the policy.